Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world. The USA-based company has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases.